- Home
- ACAD vs HWKN Comparison
ACAD vs HWKN Comparison
Compare ACAD & HWKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- HWKN
- Stock Information
- Founded
- ACAD 1993
- HWKN 1938
- Country
- ACAD United States
- HWKN United States
- Employees
- ACAD N/A
- HWKN N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- HWKN Specialty Chemicals
- Sector
- ACAD Health Care
- HWKN Consumer Discretionary
- Exchange
- ACAD Nasdaq
- HWKN Nasdaq
- Market Cap
- ACAD 2.5B
- HWKN 2.5B
- IPO Year
- ACAD 2004
- HWKN N/A
- Fundamental
- Price
- ACAD $17.44
- HWKN $119.60
- Analyst Decision
- ACAD Buy
- HWKN Strong Buy
- Analyst Count
- ACAD 15
- HWKN 1
- Target Price
- ACAD $24.21
- HWKN $160.00
- AVG Volume (30 Days)
- ACAD 1.8M
- HWKN 109.9K
- Earning Date
- ACAD 05-07-2025
- HWKN 05-14-2025
- Dividend Yield
- ACAD N/A
- HWKN 0.60%
- EPS Growth
- ACAD N/A
- HWKN 12.32
- EPS
- ACAD 1.37
- HWKN 3.91
- Revenue
- ACAD $996,283,000.00
- HWKN $952,133,000.00
- Revenue This Year
- ACAD $13.07
- HWKN $6.51
- Revenue Next Year
- ACAD $10.06
- HWKN $7.56
- P/E Ratio
- ACAD $12.74
- HWKN $30.60
- Revenue Growth
- ACAD 22.42
- HWKN 3.01
- 52 Week Low
- ACAD $13.40
- HWKN $71.98
- 52 Week High
- ACAD $20.68
- HWKN $139.55
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- HWKN 53.12
- Support Level
- ACAD $14.45
- HWKN $116.84
- Resistance Level
- ACAD $15.31
- HWKN $124.44
- Average True Range (ATR)
- ACAD 0.69
- HWKN 3.86
- MACD
- ACAD 0.37
- HWKN -0.86
- Stochastic Oscillator
- ACAD 94.92
- HWKN 27.17
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About HWKN Hawkins Inc.
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers.